---
schema_version: "secwatch.filing_event.v1"
accession: "0001380106-22-000054"
form_type: "8-K"
ticker: "RPID"
cik: "0001380106"
company_name: "RAPID MICRO BIOSYSTEMS, INC."
filed_at: "2022-12-01T23:59:59+00:00"
generated_at: "2026-06-21T10:46:05.143917+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rapid Micro Biosystems ends strategic review; no binding offers received for sale

## Summary
- Board concludes review of strategic alternatives that began August 2022; no parties submitted binding offers to acquire all outstanding shares.
- Company to continue executing current strategy: enhance commercial execution, product development, expand Growth Direct market.
- As of Q3 2022, cash, cash equivalents and investments total $150.1M with no debt; cash runway expected into 2026.
- CEO cites recent actions to right-size cost structure and manage cash to secure long runway.
- Board confident in management's strategy to drive improved performance.

## SEC filing metadata
- accession: 0001380106-22-000054
- form_type: 8-K
- ticker: RPID
- cik: 0001380106
- company_name: RAPID MICRO BIOSYSTEMS, INC.
- filed_at: 2022-12-01T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1380106/000138010622000054/0001380106-22-000054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1380106/000138010622000054/rpid-20221201.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001380106-22-000054
- JSON: https://secwatch.observer/filing/0001380106-22-000054.json
- Plain text: https://secwatch.observer/filing/0001380106-22-000054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.